N-Substituted Pyrrole Derivatives as Novel Human Immunodeficiency Virus Type 1 Entry Inhibitors That Interfere with the gp41 Six-Helix Bundle Formation and Block Virus Fusion

A recently approved peptidic human immunodeficiency virus type 1 (HIV-1) fusion inhibitor, T-20 (Fuzeon; Trimeris Inc.), has shown significant promise in clinical application for treating HIV-1-infected individuals who have failed to respond to the currently available antiretroviral drugs. However,...

Descripció completa

Dades bibliogràfiques

Publicat a:	Antimicrob Agents Chemother
Autors principals:	Jiang, Shibo, Lu, Hong, Liu, Shuwen, Zhao, Qian, He, Yuxian, Debnath, Asim K.
Format:	Artigo
Idioma:	Inglês
Publicat:	American Society for Microbiology (ASM) 2004
Matèries:	Antiviral Agents
Accés en línia:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC525433/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15504864/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.48.11.4349-4359.2004
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!